{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:17:23Z","timestamp":1707524243282},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,24]]},"DOI":"10.7759\/cureus.12886","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T15:57:30Z","timestamp":1611503850000},"source":"Crossref","is-referenced-by-count":0,"title":["Benign Presentation Following Massive Deutetrabenazine Overdose"],"prefix":"10.7759","author":[{"given":"Oluseyi","family":"Obadeyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Paxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarkis","family":"Kouyoumjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon M","year":"2017","unstructured":"Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017, 78:264-78. 10.4088\/JCP.16r10832","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7916\/d8bg304w","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln O","year":"2013","unstructured":"Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 2013, 3:1-11. 10.7916\/d8bg304w","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"ref3","article-title":"AUSTEDO (deutetrabenazine) tablets, for oral use. Prescribing information","author":"Teva Pharmaceuticals","year":"2017","unstructured":"Teva Pharmaceuticals. AUSTEDO (deutetrabenazine) tablets, for oral use. Prescribing information. North Wales, PA; 2017."},{"key":"ref4","article-title":"INGREZZA (valbenazine) capsules, for oral use. Prescribing information","author":"Neurocrine Biosciences","year":"2017","unstructured":"Neurocrine Biosciences.  INGREZZA (valbenazine) capsules, for oral use. Prescribing information.  San Diego, CA; 2017."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7916\/D8M32W3H","article-title":"Deutetrabenazine in tics associated with Tourette syndrome","volume":"6","author":"Jankovic J","year":"2016","unstructured":"Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov. 2016, 6:422. 10.7916\/D8M32W3H","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic J","year":"2016","unstructured":"Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016, 17:2461-70. 10.1080\/14656566.2016.1258063","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez HH","year":"2017","unstructured":"Fernandez HH, Factor SA, Hauser RA, et al.. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017, 88:2003-10. 10.1212\/WNL.0000000000003960","journal-title":"Neurology"},{"key":"ref8","article-title":"The pharmacokinetics of extended release SD-809, a deuterium-substituted analogue of tetrabenazine","volume":"28","author":"Stamler D","year":"2013","unstructured":"Stamler D, Brown F, Bradbury M. The pharmacokinetics of extended release SD-809, a deuterium-substituted analogue of tetrabenazine. Mov Disord. 2013, 28:765.","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington Disease: a randomized clinical trial","volume":"316","author":"Frank S","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, et al.. Effect of deutetrabenazine on chorea among patients with Huntington Disease: a randomized clinical trial. JAMA. 2016, 316:40-50. 10.1001\/jama.2016.8655","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/49130-benign-presentation-following-massive-deutetrabenazine-overdose","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:53Z","timestamp":1707507173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/49130-benign-presentation-following-massive-deutetrabenazine-overdose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,24]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.12886","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,24]]}}}